SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid discussions around the Fed's latest rate cut and its potential impact on the market, with Goldman Sachs maintaining its forecast for further cuts. Community members are debating market direction, with some anticipating continued upward momentum while others express concerns about overvaluation and potential pullbacks. Additionally, there's chatter about political and economic factors influencing market sentiment.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crowd with Knife ($CAW.X) is trending due to its listing on Coinbase, sparking excitement within the community. Discussions highlight its multi-chain functionality and fully circulated supply. Community members express bullish sentiment and are actively spreading awareness.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending due to a newly announced $1.4 billion contract to build AI-powered data centers in Southeast Asia, sparking excitement about the company's growth potential in the AI infrastructure space. The community is actively debating the legitimacy of the contract, potential revenue impact, and overall valuation in comparison to its peers. Discussions also involve upcoming events and potential partnerships, specifically around the O.N.E. Amazon initiative.

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG.X) is trending as the community rallies around the joke-inspired meme coin built on Solana, asking "What's Updog?". The community highlights its long-term presence on Solana, locked liquidity, and Jupiter Strict List inclusion. Some users are drawn to its potential for meme-driven growth, while others appreciate the project's charitable aspect.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following news of a memorandum of understanding with the U.S. Department of Energy to advance quantum technologies in space, fueling discussions about the company's role in the future of quantum computing. The community is actively debating the long-term potential of quantum technology and whether IonQ can achieve significant revenue growth to justify its valuation, with some drawing comparisons to other high-growth tech companies.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amidst discussions about the Federal Reserve's rate cut decision and its potential impact on the market, particularly tech stocks. Community members are debating whether the rate cut is already priced in, if the market will continue its upward trajectory, or if a correction is on the horizon. Geopolitical factors, such as restrictions on NVIDIA's AI chip sales to China, are also influencing the conversation.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo (MLGO) is trending amid community discussion of a potential short squeeze, fueled by its small float and high short interest. Some traders are pointing to the stock's history of volatility and previous significant runs, while others highlight the company's AI, quantum, and blockchain updates as potential catalysts. Discussions also mention the company's recent financial results and the potential for sector-wide momentum.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings ($RCAT) is trending amid discussions about a potential stock offering and its implications for the stock's momentum, with some fearing a repeat of past dilutions while others see it as a necessary step for funding expansion, particularly in the maritime drone division. Community members are actively debating the size and pricing of the offering, its potential impact on the share price, and the company's overall financial management. Despite concerns, many remain bullish on $RCAT's long-term prospects, citing potential government contracts and the company's involvement with NATO.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending as quantum computing stocks gain momentum, fueled by potential breakthroughs and real-world applications. Community members are actively discussing its valuation, revenue growth, and potential for acquisitions, along with possible government contracts. The stock is experiencing volatility as traders weigh its prospects against established players in the sector, while some express concerns over insider selling.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending as traders discuss its potential for significant growth, with some pointing to faster transaction times and lower fees compared to Bitcoin. Community members are weighing in on potential price targets, debating whether BCH can outperform BTC as market focus shifts from speculation to utility. Talk of a possible Bitcoin Cash ETF is circulating, along with the observation that BCH has been quietly gaining ground.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet

The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 122.2% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stocks to Buy for July 15th

FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025.

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?

The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

New Strong Buy Stocks for July 15th

FUTU, PAAS, RAPT, HG and IVZ have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2025.

Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's  What You Should Know

Clear Street initiated coverage of Rapt Therapeutics with a Buy rating and set a $3 price target, as the research firm has “strong conviction” in RPT904b as the company's candidate for the treatment of food allergy and chronic spontaneous urticaria (CSU).Shares of Rapt Therapeutics closed flat at $1.02 on Thursday, but rose 7.8% to $1.10 in after-hours trading.Clear Street said that RPT904b represents a "potentially best-in-class anti-IgE antibody" that rivals Xolair, the treatment jointly offered by Roche and Novartis.The firm also noted that Rapt shares have declined 76% over the past 12 months, compared to a 12% drop in the XBI biotech ETF, attributing the drop to an unrelated asset discontinuation.&nbsp;According to Clear Street, this has created a "significant opportunity" for investors.According to Rapt Therapeutics, RPT904b is a half-life extended monoclonal antibody designed to bind free human IgE, a central player in allergic inflammatory diseases.&nbsp;In early-stage trials, the candidate has shown extended pharmacokinetics and pharmacodynamics relative to Xolair, potentially enabling dosing every 8 to 12 weeks, compared to 2 to 4 weeks for omalizumab.&nbsp;It also aims to treat patients with high IgE levels or body weights who may not qualify for existing anti-IgE therapies.On May 22, UBS reduced its price target for Rapt Therapeutics to $1 from $2, while keeping its ‘Neutral’ rating unchanged.&nbsp;The research note from UBS said that the in-licensing of RPT904 as an omalizumab "bio-better" stands as a principal long-term asset for Rapt.UBS raised concerns about the short-term visibility of the addressable market but acknowledged that, although food allergy represents significant commercial potential, identifying the specific patient group in which RPT904 will show meaningful clinical results remains challenging.Meanwhile, H.C. Wainwright launched coverage for Rapt with a ‘Buy’ rating and established a $6 price target on the same day.&nbsp;The research firm highlighted RPT904 as an IgE blocker that follows a commercially validated approach to minimize target risk, referencing the proven effectiveness of omalizumab in treating food allergy, as well as asthma and chronic spontaneous urticaria cases.On Stocktwits, retail sentiment was ‘bearish’ amid ‘low’ message volume.A user expressed worries about the biotech’s cash runway.<stembedurl>https://stocktwits.com/Disrupter/message/617013073</stembedurl>The stock has declined 37.4% so far in 2025.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position

Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.”

Equity

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

RAPT
RAPT Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RAPT News

RAPT RAPT Therapeutics Inc